Kronos Bio, Inc.
KRONNASDAQHealthcare
$0.88
+$0.01(+1.49%)
Market Cap$53652896
P/E Ratio—
52W High$1.46
52W Low$0.65
Kronos Bio, Inc. (KRON) Earnings: Dates, EPS & Revenue History
Quarterly EPS vs. estimates, revenue surprises, next earnings date, and analyst consensus.
KRON · earnings · updated Jun 9, 2026
Latest Earnings
Q2 FY2025Report Date: May 8, 2025EPS Actual
-$0.14
Est. -$0.30 · +53.3%
Revenue
$0.00B
Fiscal Period
Q2 FY2025
FY ends December
Report Date
May 8, 2025
After Market Close
▲ Beat EPS✓ 1-Quarter EPS Beat Streak
KRON reports quarterly as a NASDAQ-listed Biotechnology company. Fiscal year ends in December. Data: FMP · Updated hourly.
Next Earnings Date
Days Away
84
days
Expected Date
Sep 1, 2026
Fiscal Period
Q3 FY2026
Release Time
◌ Time TBD (Unconfirmed)EPS Est.
$1.20
Rev. $4.26B
Days Away84
Expected DateSep 1, 2026
Fiscal PeriodQ3 FY2026
Release TimeTime TBD (Unconfirmed)
EPS Est.$1.20
Rev. Est.$4.26B
EPS & Revenue vs. Estimates
Actual (Beat)
Actual (Miss)
Estimated
Earnings History
| Period | Report Date | EPS Est. | EPS Actual | EPS Surpr. | Revenue | Rev. Est. | Rev. Surpr. |
|---|---|---|---|---|---|---|---|
| ▲ Q2 FY2025 | May 8, 2025 | -$0.30 | -$0.14 | +53.3% | $0.00B | — | — |
| ▼ Q1 FY2025 | Mar 18, 2025 | -$0.30 | -$0.43 | -43.3% | $0.00B | $0.00B | -6.3% |
| ▲ Q4 FY2024 | Nov 13, 2024 | -$0.26 | -$0.23 | +11.5% | $0.00B | $0.00B | -1.3% |
| ▲ Q3 FY2024 | Aug 8, 2024 | -$0.32 | -$0.27 | +15.6% | $0.00B | $0.00B | +76.8% |
| ▼ Q2 FY2024 | May 9, 2024 | -$0.43 | -$0.50 | -16.3% | $0.00B | $0.00B | +152.0% |
| ▲ Q1 FY2024 | Mar 21, 2024 | -$0.51 | -$0.43 | +15.7% | $0.00B | $0.00B | +50.4% |
| ▼ Q4 FY2023 | Nov 13, 2023 | -$0.51 | -$0.54 | -5.9% | $0.00B | $0.00B | -39.7% |
| ▼ Q3 FY2023 | Aug 8, 2023 | -$0.50 | -$0.52 | -4.0% | $0.00B | $0.00B | +11.6% |
Q2 FY2025
May 8, 2025Beat
EPS Actual
-$0.14
EPS Est.
-$0.30
EPS Surpr.
+53.3%
Revenue
$0.00B
Q1 FY2025
Mar 18, 2025Miss
EPS Actual
-$0.43
EPS Est.
-$0.30
EPS Surpr.
-43.3%
Revenue
$0.00B
Q4 FY2024
Nov 13, 2024Beat
EPS Actual
-$0.23
EPS Est.
-$0.26
EPS Surpr.
+11.5%
Revenue
$0.00B
Q3 FY2024
Aug 8, 2024Beat
EPS Actual
-$0.27
EPS Est.
-$0.32
EPS Surpr.
+15.6%
Revenue
$0.00B
Q2 FY2024
May 9, 2024Miss
EPS Actual
-$0.50
EPS Est.
-$0.43
EPS Surpr.
-16.3%
Revenue
$0.00B
Q1 FY2024
Mar 21, 2024Beat
EPS Actual
-$0.43
EPS Est.
-$0.51
EPS Surpr.
+15.7%
Revenue
$0.00B
Q4 FY2023
Nov 13, 2023Miss
EPS Actual
-$0.54
EPS Est.
-$0.51
EPS Surpr.
-5.9%
Revenue
$0.00B
Q3 FY2023
Aug 8, 2023Miss
EPS Actual
-$0.52
EPS Est.
-$0.50
EPS Surpr.
-4.0%
Revenue
$0.00B
Analyst Estimates
Limited analyst coverage (fewer than 3 analysts). Estimates may not reflect market consensus.
EPS Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q4 FY2025 | $-0.40 | $-0.40 | $-0.40 | 1 |
| Q3 FY2025 | $-0.30 | $-0.30 | $-0.30 | 1 |
| Q2 FY2025 | $-0.30 | $-0.30 | $-0.30 | 1 |
| Q1 FY2025 | $-0.30 | $-0.30 | $-0.30 | 2 |
| Q4 FY2024 | $-0.29 | $-0.29 | $-0.29 | 1 |
| Q3 FY2024 | $-0.32 | $-0.28 | $-0.21 | 3 |
Revenue Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q4 FY2025 | $0.0B | $0.0B | $0.0B | 1 |
| Q3 FY2025 | $0.0B | $0.0B | $0.0B | 1 |
| Q2 FY2025 | $0.0B | $0.0B | $0.0B | 1 |
| Q1 FY2025 | $0.0B | $0.0B | $0.0B | 1 |
| Q4 FY2024 | $0.0B | $0.0B | $0.0B | 1 |
| Q3 FY2024 | $0.0B | $0.0B | $0.0B | 3 |
Earnings Price Reaction
Closing price one trading day before vs. one trading day after each earnings release.
| Period | Report Date | EPS Beat/Miss | Price Before | Price After | 1D Reaction |
|---|---|---|---|---|---|
| ▲ Q2 FY2025 | May 8, 2025 | +53.3% | $0.72 | $0.73 | +1.33% |
| ▼ Q1 FY2025 | Mar 18, 2025 | -43.3% | $0.95 | $0.93 | -1.74% |
| ▲ Q4 FY2024 | Nov 13, 2024 | +11.5% | $0.92 | $0.88 | -4.33% |
| ▲ Q3 FY2024 | Aug 8, 2024 | +15.6% | $1.11 | $1.11 | +0.00% |
| ▼ Q2 FY2024 | May 9, 2024 | -16.3% | $1.04 | $1.05 | +0.96% |
| ▲ Q1 FY2024 | Mar 21, 2024 | +15.7% | $1.21 | $1.20 | -0.83% |
| ▼ Q4 FY2023 | Nov 13, 2023 | -5.9% | $0.80 | $0.76 | -5.51% |
| ▼ Q3 FY2023 | Aug 8, 2023 | -4.0% | $1.67 | $1.63 | -2.40% |
Q2 FY2025+1.33%
Report Date
May 8, 2025
EPS Beat/Miss
+53.3%
Price Before
$0.72
Price After
$0.73
Q1 FY2025-1.74%
Report Date
Mar 18, 2025
EPS Beat/Miss
-43.3%
Price Before
$0.95
Price After
$0.93
Q4 FY2024-4.33%
Report Date
Nov 13, 2024
EPS Beat/Miss
+11.5%
Price Before
$0.92
Price After
$0.88
Q3 FY2024+0.00%
Report Date
Aug 8, 2024
EPS Beat/Miss
+15.6%
Price Before
$1.11
Price After
$1.11
Q2 FY2024+0.96%
Report Date
May 9, 2024
EPS Beat/Miss
-16.3%
Price Before
$1.04
Price After
$1.05
Q1 FY2024-0.83%
Report Date
Mar 21, 2024
EPS Beat/Miss
+15.7%
Price Before
$1.21
Price After
$1.20
Q4 FY2023-5.51%
Report Date
Nov 13, 2023
EPS Beat/Miss
-5.9%
Price Before
$0.80
Price After
$0.76
Q3 FY2023-2.40%
Report Date
Aug 8, 2023
EPS Beat/Miss
-4.0%
Price Before
$1.67
Price After
$1.63
Avg Beat Reaction-0.96%
Avg Miss Reaction-2.17%
Beat Rate4 / 8 quarters
Largest Move-5.51% (Q4 FY2023)
Data: FMP /historical-price-eod/full · field: close
About Earnings & Data Methodology
Data source: Financial Modeling Prep (FMP) | Updated: Hourly | Surprise%: (Actual − Estimate) / |Estimate| × 100 | Fiscal year: KRON ends December
Kronos Bio, Inc. (KRON) most recently reported earnings on May 8, 2025 for Q2 FY2025, posting EPS of $-0.14 — beating the analyst consensus of $-0.30 by +53.3%. The next KRON earnings date is expected around September 1, 2026.
Each quarter, investors track KRON earnings for signals on forward guidance and business momentum. For longer-term revenue trends, see the Revenue tab. KRON revenue tab →
Earnings Glossary
EPS (Earnings Per Share)
Net income ÷ diluted shares outstanding. The primary metric analysts use to gauge quarterly profitability.
Earnings Surprise %
(Actual − Estimate) / |Estimate| × 100. Positive = Beat. Negative = Miss.
Beat / Miss / In-Line
Beat = Actual ≥ Estimate. Miss = Actual < Estimate. In-Line = within ±1%.
BMO / AMC
Before Market Open / After Market Close. Two windows when companies typically release results.
Fiscal Quarter
KRON's fiscal year ends in December. Fiscal quarters may not align with calendar quarters.
Analyst Consensus
Average EPS/Revenue forecast across all covering analysts. More analysts = more reliable estimate.
Figures tie to FMP earnings calendar, estimates, and SEC 10-Q/10-K filings where noted.
Frequently asked questions
KRON earnings · 5 questionsKronos Bio, Inc.'s next earnings report is expected around September 1, 2026. KRON typically reports quarterly — approximately every three months. The exact date is confirmed by the company 2–4 weeks before the release. Time is currently TBD; KRON historically reports after market close (AMC).
KRON earnings datewhen is KRON earningsKRON next earnings datewhen does KRON report earningsKRON earnings calendar
▸ Source: FMP · Kronos Bio, Inc. SEC filings · US GAAP · Kronos Bio, Inc. SEC 10-K & 10-Q filings · US GAAP · Updated: Jun 9, 2026